Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Enhances Dope Management And ADR Systems

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China will forbid pharmaceutical and chemical companies in China from manufacturing, selling, trading, exporting and importing any anabolic agents without the government approval, and China's State FDA will improve the adverse drug reaction report system, SFDA said at a July 8 press conference

You may also be interested in...



Opportunities Outweigh Challenges For Postmarketing Studies – BMS Exec

SHANGHAI - Both challenges and opportunities exist for conducting post-marketing safety studies for drugs, but the opportunities far outweigh the challenges, Bristol-Myers Squibb VP Medical Safety Amrit Ray said Oct. 30 at Shanghai Institute for Food and Drug Safety's 2008 Drug Safety and Public Policy International Conference

Opportunities Outweigh Challenges For Postmarketing Studies – BMS Exec

SHANGHAI - Both challenges and opportunities exist for conducting post-marketing safety studies for drugs, but the opportunities far outweigh the challenges, Bristol-Myers Squibb VP Medical Safety Amrit Ray said Oct. 30 at Shanghai Institute for Food and Drug Safety's 2008 Drug Safety and Public Policy International Conference

China Implements Credit Ratings System for Drug Advertising

SHANGHAI - China's State Food and Drug Administration announced Nov. 8 that it will implement new credit management measures to clamp down on illegal advertising of drugs, medical devices and health supplements

Related Content

UsernamePublicRestriction

Register

SC069032

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel